120 related articles for article (PubMed ID: 12197480)
1. Is BRCA1 associated with familial breast cancer in India?
Couch FJ
Cancer Biol Ther; 2002; 1(1):22-3. PubMed ID: 12197480
[No Abstract] [Full Text] [Related]
2. Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families.
Kumar BV; Lakhotia S; Ankathil R; Madhavan J; Jayaprakash PG; Nair MK; Somasundaram K
Cancer Biol Ther; 2002; 1(1):18-21. PubMed ID: 12170759
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
Meindl A;
Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
[TBL] [Abstract][Full Text] [Related]
4. [Genetic predisposition for breast cancer: BRCA1 and BRCA2 genes].
Narod SA; Rodríguez AA
Salud Publica Mex; 2011; 53(5):420-9. PubMed ID: 22218796
[TBL] [Abstract][Full Text] [Related]
5. BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.
Borg A; Dørum A; Heimdal K; Maehle L; Hovig E; Møller P
Dis Markers; 1999 Oct; 15(1-3):79-84. PubMed ID: 10595257
[TBL] [Abstract][Full Text] [Related]
6. Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families.
Kauff ND; Perez-Segura P; Robson ME; Scheuer L; Siegel B; Schluger A; Rapaport B; Frank TS; Nafa K; Ellis NA; Parmigiani G; Offit K
J Med Genet; 2002 Aug; 39(8):611-4. PubMed ID: 12161607
[No Abstract] [Full Text] [Related]
7. Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
de la Hoya M; Osorio A; Godino J; Sulleiro S; Tosar A; Perez-Segura P; Fernandez C; Rodríguez R; Díaz-Rubio E; Benítez J; Devilee P; Caldés T
Int J Cancer; 2002 Feb; 97(4):466-71. PubMed ID: 11802208
[TBL] [Abstract][Full Text] [Related]
8. Mutation analysis of the BRCA1 and BRCA2 genes in the Belgian patient population and identification of a Belgian founder mutation BRCA1 IVS5 + 3A > G.
Claes K; Machackova E; De Vos M; Poppe B; De Paepe A; Messiaen L
Dis Markers; 1999 Oct; 15(1-3):69-73. PubMed ID: 10595255
[TBL] [Abstract][Full Text] [Related]
9. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes.
Vehmanen P; Friedman LS; Eerola H; McClure M; Ward B; Sarantaus L; Kainu T; Syrjäkoski K; Pyrhönen S; Kallioniemi OP; Muhonen T; Luce M; Frank TS; Nevanlinna H
Hum Mol Genet; 1997 Dec; 6(13):2309-15. PubMed ID: 9361038
[TBL] [Abstract][Full Text] [Related]
10. Identification of a founder BRCA2 mutation in Sardinian breast cancer families.
Monne M; Piras G; Fancello P; Santona MC; Uras A; Landriscina G; Mastio G; Gabbas A
Fam Cancer; 2007; 6(1):73-9. PubMed ID: 17216544
[TBL] [Abstract][Full Text] [Related]
11. Identification of seven new BRCA1 germline mutations in Italian breast and breast/ovarian cancer families.
Montagna M; Santacatterina M; Corneo B; Menin C; Serova O; Lenoir GM; Chieco-Bianchi L; D'Andrea E
Cancer Res; 1996 Dec; 56(23):5466-9. PubMed ID: 8968102
[TBL] [Abstract][Full Text] [Related]
12. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families.
Verhoog LC; van den Ouweland AM; Berns E; van Veghel-Plandsoen MM; van Staveren IL; Wagner A; Bartels CC; Tilanus-Linthorst MM; Devilee P; Seynaeve C; Halley DJ; Niermeijer MF; Klijn JG; Meijers-Heijboer H
Eur J Cancer; 2001 Nov; 37(16):2082-90. PubMed ID: 11597388
[TBL] [Abstract][Full Text] [Related]
13. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
[TBL] [Abstract][Full Text] [Related]
14. The role of BRCA mutation testing in determining breast cancer therapy.
Trainer AH; Lewis CR; Tucker K; Meiser B; Friedlander M; Ward RL
Nat Rev Clin Oncol; 2010 Dec; 7(12):708-17. PubMed ID: 21060331
[TBL] [Abstract][Full Text] [Related]
15. Contributions of ATM mutations to familial breast and ovarian cancer.
Thorstenson YR; Roxas A; Kroiss R; Jenkins MA; Yu KM; Bachrich T; Muhr D; Wayne TL; Chu G; Davis RW; Wagner TM; Oefner PJ
Cancer Res; 2003 Jun; 63(12):3325-33. PubMed ID: 12810666
[TBL] [Abstract][Full Text] [Related]
16. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
[TBL] [Abstract][Full Text] [Related]
17. Costs and benefits of diagnosing familial breast cancer.
Heimdal K; Maehle L; Møller P
Dis Markers; 1999 Oct; 15(1-3):167-73. PubMed ID: 10595273
[TBL] [Abstract][Full Text] [Related]
18. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton DF; Ford D; Bishop DT
Am J Hum Genet; 1995 Jan; 56(1):265-71. PubMed ID: 7825587
[TBL] [Abstract][Full Text] [Related]
19. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
[TBL] [Abstract][Full Text] [Related]
20. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
Moslehi R; Chu W; Karlan B; Fishman D; Risch H; Fields A; Smotkin D; Ben-David Y; Rosenblatt J; Russo D; Schwartz P; Tung N; Warner E; Rosen B; Friedman J; Brunet JS; Narod SA
Am J Hum Genet; 2000 Apr; 66(4):1259-72. PubMed ID: 10739756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
